Vanda puts VQW-765 on hold: what it means for Vanda Pharmaceuticals stock

Published on 10/18/2026 at 13:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

VQW-765's trial enrolled 546 adults and missed its primary endpoint on October 14, 2026. For Vanda Pharmaceuticals stock, Q2 revenue was USD 50.53 million.

Pipeline setback and market context

Vanda placed VQW-765 on hold after a 546-person trial missed its endpoint on October 14, 2026.
Second-quarter 2026 revenue was USD 50.53 million, below the USD 61.92 million consensus estimate.
Vanda Pharmaceuticals stock closed at USD 4.03 on October 16, 2026, on the Nasdaq.
MarketBeat listed nine analyst ratings and a USD 13.08 average target on October 17, 2026.

VNDA, US9216591084, Illustration mit AI erstellt.

Vanda Pharmaceuticals (ISIN US9216591084) put its VQW-765 program on hold after a Phase III trial missed its primary endpoint on October 14, 2026, a setback that leaves the company's late-stage pipeline more dependent on other programs. The update was reported by BioSpace.

What does the setback mean?

Vanda's Study 3201 randomized 546 adults with social anxiety disorder. The trial failed to show a statistically significant difference from placebo in its primary endpoint among female participants, and it also missed the key secondary endpoint in the full population, according to Vanda Pharmaceuticals. Management said the program is on hold pending analysis of the full dataset.

The setback follows a positive Phase III HETLIOZ result dated September 29, 2026. Vanda said sleep onset advanced by 42.5 minutes with tasimelteon versus 5.4 minutes with placebo, giving the company a separate regulatory opportunity in delayed sleep-wake phase disorder.

Three events frame the pipeline

On August 5, 2026, Vanda reported second-quarter revenue of USD 50.53 million and a net loss of USD 62.51 million. On September 29, 2026, the company reported the HETLIOZ result with a 37.1-minute placebo-adjusted improvement. On October 14, 2026, Vanda placed VQW-765 on hold after the 546-person study missed its endpoints. The dates and figures come from Vanda Pharmaceuticals.

Revenue and analyst expectations

The second-quarter revenue result was 18.40 percent below the USD 61.92 million consensus estimate, while diluted earnings per share were a loss of USD 1.04 against a consensus loss of USD 0.58. That combination helps explain why the pipeline update matters for valuation as much as for clinical execution.

MarketBeat listed nine analyst ratings on October 17, 2026, with six buys, one hold and two sells. Its average twelve-month price target was USD 13.08, while the highest target was USD 20.00 and the lowest was USD 7.50. These targets reflect analyst views rather than a company forecast.

Next reporting date

Vanda is scheduled to report its September 2026 results on November 4, 2026, according to MetaCap. That report will give investors the next quantified read on product sales and cash use after the clinical setback.

Nasdaq closing level

On the Nasdaq, Vanda Pharmaceuticals closed at USD 4.03 on October 16, 2026 at 4:00 p.m. ET. The same market page put the 52-week range at USD 4.00 to USD 9.94 and market capitalization at USD 243.7 million.

The further course of trading is shown by the continuously updated real-time quote of Vanda Pharmaceuticals stock.